Abstract:Poor tumor perfusion and unfavorable vessel permeability compromise nanomedicine drug delivery to tumors. Captopril dilates blood vessels, reducing blood pressure clinically and bradykinin, as the downstream signaling moiety of captopril, is capable of dilating blood vessels and effectively increasing vessel permeability. The hypothesis behind this study was that captopril can dilate tumor blood vessels, improving tumor perfusion and simultaneously enlarge the endothelial gaps of tumor vessels, therefore enhancing nanomedicine drug delivery for tumor therapy. Using the U87 tumor xenograft with abundant blood vessels as the tumor model, tumor perfusion experiments were carried out using laser Doppler imaging and lectin-labeling experiments. A single treatment of captopril at a dose of 100 mg/kg significantly increased the percentage of functional vessels in tumor tissues and improved tumor blood perfusion. Scanning electron microscopy of tumor vessels also indicated that the endothelial gaps of tumor vessels were enlarged after captopril treatment. Immunofluorescence-staining of tumor slices demonstrated that captopril significantly increased bradykinin expression, possibly explaining tumor perfusion improvements and endothelial gap enlargement. Additionally, imaging in vivo, imaging ex vivo and nanoparticle distribution in tumor slices indicated that after a single treatment with captopril, the accumulation of 115-nm nanoparticles in tumors had increased 2.81-fold with a more homogeneous distribution pattern in comparison to non-captopril treated controls. Finally, pharmacodynamics experiments demonstrated that captopril combined with paclitaxel-loaded nanoparticles resulted in the greatest tumor shrinkage and the most extensive necrosis in tumor tissues among all treatment groups. Taken together, the data from the present study suggest a novel strategy for improving tumor perfusion and enlarging blood vessel permeability simultaneously in order to improve nanomedicine delivery for tumor therapy. As captopril has already been extensively used clinically, such a strategy has great therapeutic potential.

Captopril Improves Tumor Nanomedicine Delivery by Increasing Tumor Blood Perfusion and Enlarging Endothelial Gaps in Tumor Blood Vessels.

S-nitrosocaptopril Interrupts Adhesion of Cancer Cells to Vascular Endothelium by Suppressing Cell Adhesion Molecules Via Inhibition of the NF-кB and JAK/STAT Signal Pathways in Endothelial Cells

Captopril Related Kidney Damage: Renal Afferent Arteriolar Responses to Angiotensin II and Inflammatory Signaling.

S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells

Cancer-Associated Fibroblast-Targeted Delivery of Captopril to Overcome Penetration Obstacles for Enhanced Pancreatic Cancer Therapy.

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies

Captopril Inhibits the Production of Tumor Necrosis Factor-Alpha by Human Mononuclear Cells in Patients with Congestive Heart Failure

Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy Against Pancreatic Cancer

Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem

Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.

Selective Enhancing Blood Flow in Solid Tumor Tissue Is the Key for Achieving Satisfactory Delivery and Therapeutic Outcome of Nanodrugs via the EPR Effect

Normalizing Tumor Vessels to Increase the Enzyme-Induced Retention and Targeting of Gold Nanoparticle for Breast Cancer Imaging and Treatment

Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Features of Tumor Invasion and Down-Regulates C-Myc Expression in a Mouse Model of Colorectal Cancer Liver Metastasis

Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells

Nanoparticle-Mediated Drug Delivery to Tumor Neovasculature to Combat P-Gp Expressing Multidrug Resistant Cancer

Apatinib, a Selective VEGFR2 Inhibitor, Improves the Delivery of Chemotherapeutic Agents to Tumors by Normalizing Tumor Vessels in LoVo Colon Cancer Xenograft Mice.

Computational Insights into Captopril's Inhibitory Potential Against MMP9 and LCN2 in Bladder Cancer: Implications for Therapeutic Application

Enhancement of Nab-Paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer.

Tumor Priming Using Metronomic Chemotherapy with Neovasculature-Targeted, Nanoparticulate Paclitaxel

Effect of an Endothelin B Receptor Agonist on the Tumor Accumulation of Nanocarriers

Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window